论文部分内容阅读
本试验的目的是观察国产重组人白细胞介素 11(rhIL 11)皮下注射对正常小鼠和骨髓抑制小鼠的血液学效应。给正常小鼠rhIL 112 0 0及 4 0 0 μg/kg皮下注射 ,连续 7天 ,第 5天时外周血血小板数轻度升高 ,起效较平缓 ,停药后血小板数可在 4天内恢复到给药前水平。对骨髓抑制小鼠 ,rhIL 11的治疗可明显地减轻外周血小板计数的下降程度 ,促进血小板计数的恢复。rhIL 11在每天 10 0 - 4 0 0 μg/kg时对骨髓抑制小鼠均有良好疗效 ,治疗 13- 15天血小板计数恢复到照射前水平 ,在每天 4 0 0 μg/kg时起效稍快于 10 0及 2 0 0 μg/kg。上述 3个剂量所引起的血小板最大升幅十分接近。rhIL 11的升血小板作用与其促进骨髓巨核系祖细胞的增殖与成熟有关。上述结果表明 ,rhIL 11治疗无论对正常小鼠还是骨髓抑制小鼠均可提高外周血血小板数 ,提示rhIL 11可能是一种治疗血小板减少症的药物。
The purpose of this experiment was to observe the hematological effects of domestic recombinant human interleukin-11 (rhIL-11) subcutaneously on normal and myelosuppressed mice. The normal mice were injected subcutaneously with rhIL-1200 and 400 μg / kg for 7 days. On the fifth day, the platelets of peripheral blood were slightly elevated and the onset of action was gentle. The number of platelets recovered after 4 days of withdrawal Pre-dose level. In myelosuppressed mice, treatment with rhIL 11 significantly reduced the decline in peripheral platelet counts and promoted the recovery of platelet counts. rhIL11 had good efficacy on myelosuppressed mice at daily doses of 100-400 μg / kg, and platelet counts returned to pre-irradiation levels from 13 to 15 days after treatment, with slightly greater onset of effect at 400 μg / kg daily At 10 0 and 200 μg / kg. The three doses caused by the largest increase in platelets is very close. The platelet function of rhIL-11 is related to its promotion of proliferation and maturation of bone marrow megakaryocyte progenitor cells. The above results indicate that rhIL-11 treatment can increase the number of peripheral blood platelets in both normal and myelosuppressed mice, suggesting that rhIL 11 may be a therapeutic drug for thrombocytopenia.